文献速递创面修复美容整形

生物制剂在鼻重建中的应用:138例回顾性综述

"The Use of Biologic Agents in Nasal Reconstruction: A Review of 138 Cases".
PubMed 文献 · Plast Reconstr Surg · 2026-05-19

该研究回顾性分析了2013至2023年间138例使用Integra或ACell进行鼻重建的患者,鼻翼是最常见受累亚单位(25.4%),平均缺损面积6.9 cm²,ACell使用最多(73.2%),总体并发症率6.5%。研究认为生物制剂是简化、耐受性好且有效的替代方案,对高龄、吸烟及抗凝患者同样可靠。

要点

  • 鼻翼为最常见缺损亚单位(25.4%),平均缺损面积6.9 cm²。
  • ACell是最常用生物制剂(73.2%),总体并发症率6.5%。
  • 高龄、吸烟史及抗凝状态未显著增加并发症风险。

核心结论

  • 生物制剂用于鼻重建简化、耐受性好且有效,可替代多期重建手术。
  • 研究支持生物制剂在高龄、吸烟及抗凝患者中应用的可靠性。

研究设计与样本

  • 回顾性综述,纳入2013至2023年由同一资深作者(J.F.T.)使用Integra或ACell行鼻重建的138例患者。

主要发现

  • 鼻翼是最常见受累亚单位(25.4%),平均缺损面积6.9 cm²。
  • ACell为最常用生物制剂(73.2%)。
  • 总体并发症率6.5%(n=9),包括瘢痕回缩至生物制剂丢失。
  • 年龄>75岁、吸烟史及抗凝治疗与并发症率无统计学显著差异。
  • 缺损大小和位置对并发症率无显著影响。

临床怎么用

  • 鼻重建需综合评估患者与缺损变量,生物制剂可作为多期手术的简化替代方案。
  • 对高龄、吸烟及抗凝患者,生物制剂仍可考虑使用。

局限性

  • 回顾性研究设计,证据等级有限。
  • 研究仅反映单一资深作者的经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reconstruction of nasal defects can prove challenging for plastic surgeons, requiring consideration of both aesthetics and function. While many reconstructive techniques exist, the study of biologic agents in nasal reconstruction remains limited. METHODS: We conducted a retrospective review of patients who underwent nasal reconstruction using a biologic wound healing agent (Integra or ACell) from 2013 to 2023 performed by the senior author (J.F.T.). Data was collected and analyzed regarding patient demographics, defect characteristics, reconstructive modality, revisions, and complications. RESULTS: A total of 138 patients underwent nasal reconstruction using Integra or ACell. The ala was the most commonly affected subunit (25.4 percent), and the mean defect size was 6.9 cm 2. ACell was the most common biologic used for reconstruction (73.2 percent). The overall complication rate was 6.5 percent (n = 9), ranging from scar retraction to biologic loss. There were no statistically significant differences in complication rates among patients over 75 years of age, those with a history of cigarette smoking, or those on anticoagulation. Additionally, defect size and location did not significantly impact complication rates. CONCLUSIONS: Nasal reconstruction requires consideration of numerous patient and defect variables. Compared to a multi-staged reconstructive procedure, biologic agents offer a simpler, well-tolerated, and effective alternative. This study supports the reliability of biologic agents in nasal reconstruction, including in high-risk populations such as elderly patients, smokers, and those on anticoagulation therapy.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Ngo TC, Bennett A, Hollier P, et al. "The Use of Biologic Agents in Nasal Reconstruction: A Review of 138 Cases". Plast Reconstr Surg. 2026. PMID: 42153732. doi:10.1097/PRS.0000000000013185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。